ABOUT AZAD VIRK

Azad Virk is a shareholder in Stradling’s Corporate and Technology Transactions practice groups.

Azad’s practice focuses on a variety of corporate, commercial and intellectual property transactions, including the formation of startups, equity and debt financings, mergers and acquisitions, joint ventures, strategic alliances, intellectual property and technology transactions across multiple industries.

Azad practiced law in India before relocating to the United States, counseling clients on intellectual property issues and representing a diverse range of clients in intellectual property, corporate and technology-related litigation before various courts and tribunals.

Azad was named a “Southern California Rising Star” by Super Lawyers in 2015, 2016 and 2017.

Recent Speaking Engagements

“Are Your Contracts Helping or Hurting You?”, OCTANe Legal Roundtable (March 2017)
“January Brown Bag: Advanced Contract Negotiations – Avoiding Traps for the Unwary”, The Association of Corporate Counsel San Diego Chapter (January 2015)
“Advanced Contract Negotiations: Avoiding the Speed Bumps, Pitfalls and Trapdoors of Complex Contracts,” Association of Corporate Counsel (February 2012)

Featured Experience

HomeUnion, Inc. Completes $16 Million Series B Preferred Stock FinancingRepresented HomeUnion, Inc. in its $16 million Series B Preferred Stock offering to existing and new investors, including lead investors Artiman Ventures and Colchis Capital.
Spectrum Pharmaceuticals Enters Into License and Asset Purchase Agreement with MundipharmaAdvised Spectrum Pharmaceuticals Cayman, L.P., a wholly-owned subsidiary of Stradling client Spectrum Pharmaceuticals, Inc., on a license and asset purchase agreement with Mundipharma International Corporation Limited regarding the exclusive commercialization rights to ZEVALIN in Asia, excluding India and Greater China, Australia/New Zealand, Africa, the Middle East, and Latin America (including the Caribbean). Pursuant to the terms of the transaction, Spectrum Pharmaceuticals Cayman will receive $20 million, comprised of an upfront payment of $15 million plus $5 million in profits on the initial ZEVALIN supply.
Vessix Vascular Completes Its Sale to Boston Scientific CorporationStradling represented Vessix Vascular in its acquisition by Boston Scientific Corporation for up to $425 million.
BarioSurg, Inc. Completes Merger With EnteroMedics Inc.Represented BarioSurg, Inc. in its merger of equals with EnteroMedics Inc., a publicly traded Delaware corporation (NASDAQ CM:ETRM), whereby Enteromedics acquired all of the equity of BarioSurg in exchange for the issuance of 1,380,684 shares of Enteromedics Common Stock, 1,000,181 shares of Enteromedics newly created Convertible Preferred Stock (convertible into approximately five million shares of Enteromedics Common Stock upon approval of Enteromedics’ stockholders) and $2 million in cash (less transaction expenses).
Spectrum Pharmaceuticals, Inc. Executes $6 Million License and Supply Agreements With Servier Canada, Inc.Represented Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) in the execution of license and supply agreements in connection with its strategic partnership with Servier Canada, Inc. for the out-license of commercialization rights to ZEVALIN®, FOLOTYN®, BELEODAQ®, and MARQIBO® in Canada.
HomeUnion, Inc. Completes $16 Million Series B Preferred Stock FinancingRepresented HomeUnion, Inc. in its $16 million Series B Preferred Stock offering to existing and new investors, including lead investors Artiman Ventures and Colchis Capital.
Spectrum Pharmaceuticals Enters Into License and Asset Purchase Agreement with MundipharmaAdvised Spectrum Pharmaceuticals Cayman, L.P., a wholly-owned subsidiary of Stradling client Spectrum Pharmaceuticals, Inc., on a license and asset purchase agreement with Mundipharma International Corporation Limited regarding the exclusive commercialization rights to ZEVALIN in Asia, excluding India and Greater China, Australia/New Zealand, Africa, the Middle East, and Latin America (including the Caribbean). Pursuant to the terms of the transaction, Spectrum Pharmaceuticals Cayman will receive $20 million, comprised of an upfront payment of $15 million plus $5 million in profits on the initial ZEVALIN supply.
Vessix Vascular Completes Its Sale to Boston Scientific CorporationStradling represented Vessix Vascular in its acquisition by Boston Scientific Corporation for up to $425 million.

Education

Stanford Law School, LL.M., 2007
University of London, Queen Mary & Westfield College, LL.M., 2000
Panjab University, LL.B., 1999
Panjab University, B.A., 1996

Memberships & Associations

International Association for the Protection of Intellectual Property

Bar Admissions

California
Punjab & Haryana High Court Bar Association